JP2010536880A - 糖尿病の合併症のための療法 - Google Patents

糖尿病の合併症のための療法 Download PDF

Info

Publication number
JP2010536880A
JP2010536880A JP2010522066A JP2010522066A JP2010536880A JP 2010536880 A JP2010536880 A JP 2010536880A JP 2010522066 A JP2010522066 A JP 2010522066A JP 2010522066 A JP2010522066 A JP 2010522066A JP 2010536880 A JP2010536880 A JP 2010536880A
Authority
JP
Japan
Prior art keywords
selective
receptor antagonist
receptor
use according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536880A5 (cg-RX-API-DMAC7.html
Inventor
ボーデン，ロバート・エル
ゴルチンスキ，リチャード・ジェイ
ガーバー，マイケル・ジェイ
Original Assignee
ギリード・コロラド・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリード・コロラド・インコーポレーテッド filed Critical ギリード・コロラド・インコーポレーテッド
Publication of JP2010536880A publication Critical patent/JP2010536880A/ja
Publication of JP2010536880A5 publication Critical patent/JP2010536880A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010522066A 2007-08-22 2008-08-22 糖尿病の合併症のための療法 Pending JP2010536880A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95730007P 2007-08-22 2007-08-22
PCT/US2008/074013 WO2009026517A2 (en) 2007-08-22 2008-08-22 Therapy for complications of diabetes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013183975A Division JP2014001234A (ja) 2007-08-22 2013-09-05 糖尿病の合併症のための療法
JP2014198604A Division JP2015028062A (ja) 2007-08-22 2014-09-29 糖尿病の合併症のための療法

Publications (2)

Publication Number Publication Date
JP2010536880A true JP2010536880A (ja) 2010-12-02
JP2010536880A5 JP2010536880A5 (cg-RX-API-DMAC7.html) 2011-10-06

Family

ID=40220116

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010522066A Pending JP2010536880A (ja) 2007-08-22 2008-08-22 糖尿病の合併症のための療法
JP2013183975A Pending JP2014001234A (ja) 2007-08-22 2013-09-05 糖尿病の合併症のための療法
JP2014198604A Pending JP2015028062A (ja) 2007-08-22 2014-09-29 糖尿病の合併症のための療法
JP2015214045A Pending JP2016053057A (ja) 2007-08-22 2015-10-30 糖尿病の合併症のための療法
JP2017035751A Pending JP2017145251A (ja) 2007-08-22 2017-02-28 糖尿病の合併症のための療法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013183975A Pending JP2014001234A (ja) 2007-08-22 2013-09-05 糖尿病の合併症のための療法
JP2014198604A Pending JP2015028062A (ja) 2007-08-22 2014-09-29 糖尿病の合併症のための療法
JP2015214045A Pending JP2016053057A (ja) 2007-08-22 2015-10-30 糖尿病の合併症のための療法
JP2017035751A Pending JP2017145251A (ja) 2007-08-22 2017-02-28 糖尿病の合併症のための療法

Country Status (5)

Country Link
US (5) US20090054473A1 (cg-RX-API-DMAC7.html)
EP (2) EP2190433A2 (cg-RX-API-DMAC7.html)
JP (5) JP2010536880A (cg-RX-API-DMAC7.html)
CA (2) CA2904447C (cg-RX-API-DMAC7.html)
WO (1) WO2009026517A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017145251A (ja) * 2007-08-22 2017-08-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 糖尿病の合併症のための療法
JP2020508339A (ja) * 2017-02-27 2020-03-19 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ４−ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤
JP2021523125A (ja) * 2018-05-03 2021-09-02 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
AU2008282773B8 (en) 2007-07-31 2013-03-07 Gilead Sciences, Inc. Metabolites and derivatives of ambrisentan
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
PL2424530T3 (pl) * 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
AU2015342929A1 (en) * 2014-11-07 2017-05-25 Abbvie Inc. Methods of treating CKD using predictors of fluid retention
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US10369156B2 (en) * 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
KR20250052479A (ko) 2017-01-25 2025-04-18 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US20190260657A1 (en) * 2018-02-21 2019-08-22 Cisco Technology, Inc. In-band performance loss measurement in ipv6/srv6 software defined networks
WO2019226417A1 (en) * 2018-05-23 2019-11-28 University Of Miami Methods of treating renal disease associated with chronic kidney disease such as alport syndrome
BR112021001374A2 (pt) * 2018-07-26 2021-07-06 The George Inst For Global Health composições para o tratamento da hipertensão
IL292350A (en) 2019-10-30 2022-06-01 Perfuse Therapeutics Inc Treatment of ocular diseases using endothelin receptor antagonists
MX2022007471A (es) 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
CN115803028A (zh) 2020-07-10 2023-03-14 阿斯利康(瑞典)有限公司 用于治疗慢性肾病的齐泊腾坦和达格列净的组合
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
CN116804048B (zh) * 2023-02-24 2024-11-15 中国农业大学 豌豆白蛋白分离肽、组合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
KR950000167A (ko) * 1993-06-24 1995-01-03 다께다 구니오 항-엔도테린 물질의 서방 제제
US7208517B1 (en) * 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
JP3741441B2 (ja) 1994-08-19 2006-02-01 アボツト・ラボラトリーズ エンドセリン・アンタゴニスト
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
CA2634973A1 (en) 1996-02-13 1997-08-21 Abbott Laboratories Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2001512119A (ja) 1997-08-04 2001-08-21 アボット・ラボラトリーズ エンドセリン拮抗薬
US7445792B2 (en) * 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
ES2214734T3 (es) 1997-09-26 2004-09-16 ABBOTT GMBH & CO. KG Antagonista de la endotelina e inhibidor del sistema renina-angiotensina como preparado de combinacion.
DE19743140A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19744799A1 (de) 1997-10-10 1999-04-15 Knoll Ag Pharmazeutische Kombinationspräparate
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
WO2000015599A1 (en) 1998-09-14 2000-03-23 Abbott Laboratories Process for producing stereoselective nitro compounds
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6238708B1 (en) * 1999-02-23 2001-05-29 The Iams Company Composition and process for controlling glucose metabolism in companion animals by dietary starch
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
JP2005503339A (ja) 2001-04-11 2005-02-03 アボット・ラボラトリーズ 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030022811A1 (en) * 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
ATE342261T1 (de) * 2001-09-21 2006-11-15 Novartis Pharma Gmbh Pyranderivate als inhibitoren von ace und nep
WO2003080038A1 (en) * 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
WO2005077413A1 (en) * 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
AU2005224014B9 (en) * 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
ATE534424T1 (de) * 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034084A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
WO2006126695A1 (ja) * 2005-05-23 2006-11-30 Japan Tobacco Inc. ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬
US20080132710A1 (en) * 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
WO2009026517A2 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US20100184026A1 (en) * 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013010889; Ｅｎｄｏｃｒｉｎｅ，　Ｍｅｔａｂｏｌｉｃ　＆　Ｉｍｍｕｎｅ　Ｄｉｓｏｒｄｅｒｓ　-　Ｄｒｕｇ　Ｔａｒｇｅｔｓ ７，　２, 200706, ｐ．８３-９２ *
JPN6013010891; ＮＥＰＨＲＯＮ ８７，　２, 2001, ｐ．１６１-１６９ *
JPN6013010893; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｔｈｅｒａｐｅｕｔｉｃｓ ２９３，　２, 2000, ｐ．３５１-３５９ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017145251A (ja) * 2007-08-22 2017-08-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 糖尿病の合併症のための療法
JP2020508339A (ja) * 2017-02-27 2020-03-19 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ４−ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤
JP7223701B2 (ja) 2017-02-27 2023-02-16 イドーシア ファーマシューティカルズ リミテッド ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤
JP2021523125A (ja) * 2018-05-03 2021-09-02 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
JP7458032B2 (ja) 2018-05-03 2024-03-29 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Also Published As

Publication number Publication date
US8865650B2 (en) 2014-10-21
JP2015028062A (ja) 2015-02-12
US20150051234A1 (en) 2015-02-19
CA2904447A1 (en) 2009-02-26
US20130178424A1 (en) 2013-07-11
US9592231B2 (en) 2017-03-14
WO2009026517A2 (en) 2009-02-26
WO2009026517A3 (en) 2009-05-28
US8623819B2 (en) 2014-01-07
CA2697057A1 (en) 2009-02-26
US20170079978A1 (en) 2017-03-23
CA2904447C (en) 2017-01-03
EP2190433A2 (en) 2010-06-02
JP2016053057A (ja) 2016-04-14
EP2545920A1 (en) 2013-01-16
US20140073574A1 (en) 2014-03-13
US20090054473A1 (en) 2009-02-26
JP2017145251A (ja) 2017-08-24
JP2014001234A (ja) 2014-01-09

Similar Documents

Publication Publication Date Title
US8865650B2 (en) Therapy for complications of diabetes
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2022020624A (ja) 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
CN1474690A (zh) 用于治疗心血管疾病的含有肾素抑制剂的协同性药物联合形式
US20090221549A1 (en) Antihypertensive therapy
US20070196510A1 (en) Method for treating resistant hypertension
EP2029137A2 (en) Antihypertensive therapy method
Goebel et al. Effective treatment of hypertension by AT1 receptor antagonism: the past and future of telmisartan
ES2979279T3 (es) Telmisartán para la profilaxis o el tratamiento de la hipertensión en gatos
JP2018521077A (ja) 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
WO2006130901A1 (en) Control of metabolic abnormalities
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
HK1180956A (en) Therapy for complications of diabetes
WO2025125409A1 (en) Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
CN119255805A (zh) 用于治疗高血压的阿普昔腾坦
TW202216147A (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130614

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140929